Publication

Mastocytosis: A disease at the crossroads of hematology and allergology

van Anrooij, B., 2019, [Groningen]: University of Groningen. 207 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard

Documents

  • Title and contents

    Final publisher's version, 238 KB, PDF document

  • Chapter 1

    Final publisher's version, 435 KB, PDF document

  • Chapter 2

    Final publisher's version, 147 KB, PDF document

  • Chapter 3

    Final publisher's version, 516 KB, PDF document

  • Chapter 4

    Final publisher's version, 555 KB, PDF document

  • Chapter 5

    Final publisher's version, 754 KB, PDF document

  • Chapter 6

    Final publisher's version, 575 KB, PDF document

  • Chapter 7

    Final publisher's version, 924 KB, PDF document

  • Chapter 8

    Final publisher's version, 612 KB, PDF document

  • Chapter 9

    Final publisher's version, 559 KB, PDF document

  • Chapter 10

    Final publisher's version, 385 KB, PDF document

  • Chapter 11

    Final publisher's version, 377 KB, PDF document

  • Complete thesis

    Final publisher's version, 3 MB, PDF document

  • Propositions

    Final publisher's version, 315 KB, PDF document

  • Bjorn van Anrooij
Mastocytosis is a rare disease that combines both allergology and hematology in that patients suffer from malignant white blood cells that induce many of the symptoms of allergic diseases. In this thesis we describe the symptoms these patients suffer from, such: as fatigue, itching, flushing and at times life threatening allergic reactions to insect sting. We also describe how these symptoms and risks affect the quality of life of these mastocytosis patients and how this burden van be measured using symptom scoring forms. Moreover, we describe a model that can help us predicting and identify those patients most at risk of these severe allergic reactions to insect stings. Finally, we describe the effect of a novel ‘chemotherapy’ compound called midostaurin on reducing these allergy like symptoms. Midostaurin appears to be a safe and reasonable effective method for symptom reduction in these severely afflicted mastocytosis patients.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Supervisors/Advisors
Award date22-May-2019
Place of Publication[Groningen]
Publisher
Print ISBNs978-94-034-1785-1
Electronic ISBNs978-94-034-1784-4
Publication statusPublished - 2019

Download statistics

No data available

ID: 82944995